Skip to main content
Top
Published in: International Urogynecology Journal 6/2006

01-11-2006 | Original Article

Duloxetine treatment for women awaiting continence surgery

Authors: J. R. A. Duckett, I. Aggarwal, A. Patil

Published in: International Urogynecology Journal | Issue 6/2006

Login to get access

Abstract

The study assessed the effect of offering a 4-week course of duloxetine therapy to 73 women awaiting a tension-free vaginal tape (TVT) operation. Twenty-seven women (37%) declined taking the drug, leaving 46 women (63%) willing to take drug therapy. Thirteen women were scheduled for a TVT with concurrent prolapse surgery, and 1 of these women decided that she no longer needed the surgery. Eight of the 33(24%) women scheduled for a TVT without concurrent prolapse surgery came off the waiting list. Nine women of the 33 women scheduled for a TVT without concurrent surgery (27%) found that the medication did not work sufficiently well. Sixteen of the 33 women (48%) discontinued medication due to side-effects. Women on a waiting list for surgery may be unwilling to take duloxetine therapy and less tolerant of side-effects.
Literature
1.
go back to reference Hampel C, Weinhold D, Benken N, Eggersmann C, Thuroff JW (1997) Definition of overactive bladder and epidemiology of urinary incontinence. Urology 50:4–14PubMedCrossRef Hampel C, Weinhold D, Benken N, Eggersmann C, Thuroff JW (1997) Definition of overactive bladder and epidemiology of urinary incontinence. Urology 50:4–14PubMedCrossRef
2.
go back to reference Bymaster FP, Dreshfiel-Ahmad LJ, Threlkeld PG et al (2001) Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25:871–880PubMedCrossRef Bymaster FP, Dreshfiel-Ahmad LJ, Threlkeld PG et al (2001) Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25:871–880PubMedCrossRef
3.
go back to reference Van Kerrebroeck P, Abrams P, Lange R et al (2004) Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. Br J Obstet Gynaecol 11:249–257 Van Kerrebroeck P, Abrams P, Lange R et al (2004) Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. Br J Obstet Gynaecol 11:249–257
4.
go back to reference Millard RJ, Moore K, Reneken R et al (2004) Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomised clinical trial. BJU Int 93:311–318PubMedCrossRef Millard RJ, Moore K, Reneken R et al (2004) Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomised clinical trial. BJU Int 93:311–318PubMedCrossRef
5.
go back to reference Dmochowski RR, Miklos JR, Norton PA et al (2004) Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol 170:1259–1263CrossRef Dmochowski RR, Miklos JR, Norton PA et al (2004) Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol 170:1259–1263CrossRef
6.
go back to reference Norton PA, Zinner NR, Yalcin I, Bump RC (2002) Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 187:40–48PubMedCrossRef Norton PA, Zinner NR, Yalcin I, Bump RC (2002) Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 187:40–48PubMedCrossRef
7.
go back to reference Bump RC, Norton PA, Zinner NR, Yalcin I (2003) Mixed urinary incontinence symptoms: urodynamic findings incontinence severity, and treatment response. Obstet Gynecol 102:76–83PubMedCrossRef Bump RC, Norton PA, Zinner NR, Yalcin I (2003) Mixed urinary incontinence symptoms: urodynamic findings incontinence severity, and treatment response. Obstet Gynecol 102:76–83PubMedCrossRef
8.
go back to reference Cardozo L, Drutz HP, Baygani SK, Bump RC (2004) Pharmacological treatment of women awaiting surgery for stress incontinence. Obstet Gynecol 104:511–519PubMed Cardozo L, Drutz HP, Baygani SK, Bump RC (2004) Pharmacological treatment of women awaiting surgery for stress incontinence. Obstet Gynecol 104:511–519PubMed
9.
go back to reference Yalcin I, Bump RC (2003) Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol 189:98–101PubMedCrossRef Yalcin I, Bump RC (2003) Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol 189:98–101PubMedCrossRef
10.
go back to reference Gurwitz JH, Sykora K, Mamdani M et al (2005) Readers guide to critical appraisal of cohort studies: 1. Role and design. BMJ 330:895–897PubMedCrossRef Gurwitz JH, Sykora K, Mamdani M et al (2005) Readers guide to critical appraisal of cohort studies: 1. Role and design. BMJ 330:895–897PubMedCrossRef
11.
go back to reference Ward K, Hilton P (2002) Prospective multicentre randomised trial of tension-free vaginal tape and colposuspension as primary treatment for stress incontinence. BMJ 325:67–70PubMedCrossRef Ward K, Hilton P (2002) Prospective multicentre randomised trial of tension-free vaginal tape and colposuspension as primary treatment for stress incontinence. BMJ 325:67–70PubMedCrossRef
Metadata
Title
Duloxetine treatment for women awaiting continence surgery
Authors
J. R. A. Duckett
I. Aggarwal
A. Patil
Publication date
01-11-2006
Publisher
Springer-Verlag
Published in
International Urogynecology Journal / Issue 6/2006
Print ISSN: 0937-3462
Electronic ISSN: 1433-3023
DOI
https://doi.org/10.1007/s00192-005-0063-9

Other articles of this Issue 6/2006

International Urogynecology Journal 6/2006 Go to the issue